Northern Trust’s Hepion Pharmaceuticals HEPA Stock Holding History

Northern Trust’s Portfolio HEPA Stock Details HEPA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-132	Closed	-$103K	–	4557
2023 Q1	$103K	Hold	132	–	–	﹤0.01%	4080
2022 Q4	$39.7K	Hold	132	–	–	﹤0.01%	4339
2022 Q3	$67K	Sell	132 -1	-0.8%	-$611	﹤0.01%	4239
2022 Q2	$77K	Sell	133 -9	-6%	-$7.49K	﹤0.01%	4270
2022 Q1	$184K	Buy	142 +1	+0.7%	+$1.1K	﹤0.01%	4162
2021 Q4	$161K	Sell	141 -2	-1%	-$2.74K	﹤0.01%	4274
2021 Q3	$220K	Sell	143 -3	-2%	-$4.8K	﹤0.01%	4134
2021 Q2	$288K	Hold	146	–	–	﹤0.01%	3960
2021 Q1	$268K	Buy	146 +83	+132%	+$182K	﹤0.01%	4017
2020 Q4	$139K	Buy	+63	New	+$163K	﹤0.01%	4048
2019 Q2	–	Hold	0	–	-$4K	–	4282
2019 Q1	–	Hold	0	–	–	–	4201
2018 Q4	–	Hold	0	–	–	–	4228
2018 Q3	–	Hold	0	–	–	–	4245
2018 Q2	–	Hold	0	–	–	–	4193
2018 Q1	–	Hold	0	–	–	–	4146
2017 Q4	–	Hold	0	–	–	–	4095
2017 Q3	–	Hold	0	–	–	–	4044
2017 Q2	–	Hold	0	–	–	–	4051
2017 Q1	–	Hold	0	–	–	–	3792
2016 Q4	–	Hold	0	–	–	–	3871
2016 Q3	–	Hold	0	–	–	–	4111
2016 Q2	–	Hold	0	–	–	–	4126
2016 Q1	–	Hold	0	–	–	–	4127
2015 Q4	–	Hold	0	–	–	–	4144

Other funds holding HEPA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust's HEPA Position: Q2 2023 in Review

Northern Trust sold out of Hepion Pharmaceuticals (HEPA) in Q2 2023, closing a stake of 132 shares — an estimated $103K sold.

Northern Trust first reported a position in HEPA in Q4 2020 and held it in 10 quarters. The position peaked at $288K in Q2 2021. 16 funds tracked by Wall St. Rank hold HEPA as of Q2 2023.

Northern Trust reported no remaining Hepion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Northern Trust sold 132 Hepion Pharmaceuticals shares in Q2 2023, an estimated $103K.
Northern Trust first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Northern Trust's Hepion Pharmaceuticals position peaked at $288K in Q2 2021.
16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2023.

Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.